Editas Medicine Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
1.34
0.13
(10.74%)
Volume:
4,559,432
52 week range:
1.12 - 11.58
Market Cap:
110.614M
Company Description:
Editas Medicine, Inc. focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.